Literature DB >> 11352980

Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis.

H U Marschall1, U Broomé, C Einarsson, G Alvelius, H G Thomas, S Matern.   

Abstract

Significant amounts of ursodeoxycholic acid (UDCA) used for the treatment of patients with primary biliary cirrhosis (PBC) become epimerized at C-3 to isoUDCA. We investigated the metabolism of isoUDCA and a possible pharmacologic effect in five patients (51.4 +/- 5.8 years old; 3 females, 2 males) with PBC and persistent elevations of gamma-glutamyl transpeptidase (gamma-GT) and alkaline phosphatase despite treatment with UDCA for more than one year. Serum samples were analyzed for bile acid metabolites and surrogate markers of cholestasis in 4-week intervals after 1 g/d UDCA, wash-out, 0.5 g/d isoUDCA, 0.75 g/d isoUDCA, 0.75 g/d UDCA, and two further periods with 1 g/d UDCA. Bile acids in urine were analyzed after wash-out, 0.5 and 0.75 g/d isoUDCA, and 0.75 and 1 g/d UDCA. During wash-out, AST, AP, and gamma-GT rose significantly (P < 0.05) but reversed to previous levels during the first isoUDCA period, with 0.5 g/d only. No further improvements were observed after increasing the dose of isoUDCA or switching back to UDCA. In serum, the relative amounts of isoUDCA and UDCA were 8.1 +/- 7.4% and 16.2 +/- 6.4% during 0.5 g/d isoUDCA, 6.2 +/- 2.5% and 45.0 +/- 4.1% during 0.75 g/d isoUDCA, and 0.5;-3% and 56.4;-60.0%, respectively, during UDCA. In urine, UDCA was the predominant bile acid both during isoUDCA and UDCA medications. The similar serum enrichment and urinary excretion of UDCA during administration of either isoUDCA or UDCA together with low concentrations of the intermediate of isomerization, 3-dehydro-UDCA, indicate a first-pass epimerization of isoUDCA to UDCA in the liver. Approximately 25% of serum isoUDCA and 10% of serum UDCA were conjugated with either glucuronic acid or N-acetylglucosamine, indicating hepatic formation and systemic secretion of glycosidic conjugates. In PBC patients, isoUDCA becomes isomerized to UDCA and has similar effects on surrogate markers of cholestasis. Thus, isoUDCA has pro-drug characteristics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352980

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites.

Authors:  Shadi Abu-Hayyeh; Pablo Martinez-Becerra; Siti H Sheikh Abdul Kadir; Clare Selden; Marta R Romero; Myrddin Rees; Hanns-Ulrich Marschall; Jose J G Marin; Catherine Williamson
Journal:  J Biol Chem       Date:  2010-02-20       Impact factor: 5.157

2.  Structural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids.

Authors:  Pablo M González; Carlos F Lagos; Weslyn C Ward; James E Polli
Journal:  Mol Pharm       Date:  2013-12-26       Impact factor: 4.939

3.  Expanded substrate screenings of human and Drosophila type 10 17beta-hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism: characterization of multifunctional 3alpha/7alpha/7beta/17beta/20beta/21-HSD.

Authors:  Naeem Shafqat; Hanns-Ulrich Marschall; Charlotta Filling; Erik Nordling; Xiao-Qiu Wu; Lars Björk; Johan Thyberg; Eva Mårtensson; Samina Salim; Hans Jörnvall; Udo Oppermann
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

Review 4.  Bile salts of vertebrates: structural variation and possible evolutionary significance.

Authors:  Alan F Hofmann; Lee R Hagey; Matthew D Krasowski
Journal:  J Lipid Res       Date:  2009-07-28       Impact factor: 5.922

5.  Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.

Authors:  Ornella Baisini; Federica Benini; Felice Petraglia; Wilhelm Kuhnz; Santo Scalia; Hanns-Ulrich Marschall; Gabriele Brunetti; Horst-Dietmar Tauschel; Alberto Lanzini
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 6.  Intestinal transport and metabolism of bile acids.

Authors:  Paul A Dawson; Saul J Karpen
Journal:  J Lipid Res       Date:  2014-09-10       Impact factor: 5.922

Review 7.  Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades.

Authors:  Alan F Hofmann; Lee R Hagey
Journal:  J Lipid Res       Date:  2014-05-17       Impact factor: 5.922

8.  Secondary (iso)BAs cooperate with endogenous ligands to activate FXR under physiological and pathological conditions.

Authors:  Alex Zaufel; Sandra M W van de Wiel; Lu Yin; Günter Fauler; Daphne Chien; Xinzhong Dong; John F Gilmer; Jennifer K Truong; Paul A Dawson; Stan F J van de Graaf; Peter Fickert; Tarek Moustafa
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-04-22       Impact factor: 5.187

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.